Search

Your search keyword '"Rieger CT"' showing total 1 results
Start Over Author "Rieger CT" Journal european journal of haematology

Refine your results

1 results on '"Rieger CT"'

1. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.

Author

Alig SK, Dreyling M, Seppi B, Aulinger B, Witkowski L, and Rieger CT

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brentuximab Vedotin, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Etoposide therapeutic use, Humans, Lymphoma, Large-Cell, Anaplastic pathology, Male, Middle Aged, Neoplasm Recurrence, Local, Prednisolone therapeutic use, Remission Induction, Syndrome, Treatment Outcome, Vincristine therapeutic use, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Cytokines metabolism, Immunoconjugates administration & dosage, Immunoconjugates adverse effects, Lymphoma, Large-Cell, Anaplastic complications, Lymphoma, Large-Cell, Anaplastic drug therapy
Abstract

Brentuximab Vedotin is an antibody - drug conjugate targeting CD30. We report a case of severe cytokine release syndrome (CRS) after administration of the first dose of Brentuximab Vedotin in a 64-yr-old patient with relapsed systemic anaplastic large cell lymphoma (sALCL). To our knowledge, this is the first case of CRS to Brentuximab Vedotin described in the literature. However, CRS to Brentuximab Vedotin might be underestimated, as the drug has not been tested in large phase III trials yet., (© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results